補體成分6

補體成分6
已知的結構
PDB直系同源搜索: PDBe RCSB
PDBID列表

3T5O、​4A5W、​4E0S

識別號
别名C6;, complement C6
外部IDOMIM:217050 MGI:88233 HomoloGene:47 GeneCards:C6
相關疾病
complement component 9 deficiency[1]
基因位置(人类
5號染色體
染色体5號染色體[2]
5號染色體
補體成分6的基因位置
補體成分6的基因位置
基因座5p13.1起始41,142,116 bp[2]
终止41,261,438 bp[2]
基因位置(小鼠
小鼠15号染色体
染色体小鼠15号染色体[3]
小鼠15号染色体
補體成分6的基因位置
補體成分6的基因位置
基因座15 A1|15 1.97 cM起始4,756,657 bp[3]
终止4,844,449 bp[3]
基因本體
分子功能 血浆蛋白结合
細胞組分 細胞外區域
外排體
補體系統膜攻擊複合物
生物學過程 positive regulation of activation of membrane attack complex
immune system process
complement activation
in utero embryonic development
細胞溶解
regulation of complement activation
免疫反应
positive regulation of angiogenesis
經典途徑
positive regulation of complement activation
先天免疫系統
Sources:Amigo / QuickGO
直系同源
物種人類小鼠
Entrez

729

12274

Ensembl

ENSG00000039537

ENSMUSG00000022181

UniProt

P13671

无数据

mRNA​序列

NM_000065
​NM_001115131

NM_016704

蛋白序列

NP_000056
​NP_001108603

无数据

基因位置​(UCSC)Chr 5: 41.14 – 41.26 MbChr 15: 4.76 – 4.84 Mb
PubMed​查找[4][5]
維基數據
檢視/編輯人類檢視/編輯小鼠

補體成分C6(Complement component 6),在人體內是一個由C6基因編碼的蛋白質,是補體系統的一部分,功能是形成膜攻擊複合物(MAC)。C6缺陷的患者更易被細菌感染[6][7]:41-45

參考

  1. ^ 與補體成分6相關的疾病;在維基數據上查看/編輯參考. 
  2. ^ 2.0 2.1 2.2 GRCh38: Ensembl release 89: ENSG00000039537 - Ensembl, May 2017
  3. ^ 3.0 3.1 3.2 GRCm38: Ensembl release 89: ENSMUSG00000022181 - Ensembl, May 2017
  4. ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  5. ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  6. ^ Entrez Gene: complement component 6. 
  7. ^ 曹雪濤等. 醫學免疫學 第6版. 北京: 人民衛生出版社. 2013. ISBN 978-7-117-17101-4. 

拓展閱讀

  • Davila S, Froeling FE, Tan A, et al. New genetic associations detected in a host response study to hepatitis B vaccine.. Genes Immun. 2010, 11 (3): 232–8. PMID 20237496. doi:10.1038/gene.2010.1. 
  • Rajaraman P, Brenner AV, Butler MA, et al. Common variation in genes related to innate immunity and risk of adult glioma.. Cancer Epidemiol. Biomarkers Prev. 2009, 18 (5): 1651–8. PMC 2771723可免费查阅. PMID 19423540. doi:10.1158/1055-9965.EPI-08-1041. 
  • Cerhan JR, Novak AJ, Fredericksen ZS, et al. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes.. Br. J. Haematol. 2009, 145 (5): 614–23. PMC 2820509可免费查阅. PMID 19344414. doi:10.1111/j.1365-2141.2009.07675.x. 
  • Han S, Lan Q, Park AK, et al. Polymorphisms in innate immunity genes and risk of childhood leukemia.. Hum. Immunol. 2010, 71 (7): 727–30. PMC 2967770可免费查阅. PMID 20438785. doi:10.1016/j.humimm.2010.04.004. 
  • Liu T, Qian WJ, Gritsenko MA, et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. J. Proteome Res.: 2070–80. PMC 1850943可免费查阅. PMID 16335952. doi:10.1021/pr0502065. 
  • Kimura K, Wakamatsu A, Suzuki Y, et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.. Genome Res. 2006, 16 (1): 55–65. PMC 1356129可免费查阅. PMID 16344560. doi:10.1101/gr.4039406. 
  • Talmud PJ, Drenos F, Shah S, et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.. Am. J. Hum. Genet. 2009, 85 (5): 628–42. PMC 2775832可免费查阅. PMID 19913121. doi:10.1016/j.ajhg.2009.10.014. 
  • Müller-Eberhard HJ. Molecular organization and function of the complement system.. Annu. Rev. Biochem. 1988, 57: 321–47. PMID 3052276. doi:10.1146/annurev.bi.57.070188.001541. 
  • Gerhard DS, Wagner L, Feingold EA, et al. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res. 2004, 14 (10B): 2121–7. PMC 528928可免费查阅. PMID 15489334. doi:10.1101/gr.2596504. 
  • Eid NA, Hussein AA, Elzein AM, et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring.. Malar. J. 2010, 9: 119. PMC 2877684可免费查阅. PMID 20459687. doi:10.1186/1475-2875-9-119. 
  • Fosbrink M, Cudrici C, Tegla CA, et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.. Exp. Mol. Pathol. 2009, 86 (2): 87–94. PMC 2699899可免费查阅. PMID 19162005. doi:10.1016/j.yexmp.2008.12.005. 
  • Rajaraman P, Brenner AV, Neta G, et al. Risk of meningioma and common variation in genes related to innate immunity.. Cancer Epidemiol. Biomarkers Prev. 2010, 19 (5): 1356–61. PMC 3169167可免费查阅. PMID 20406964. doi:10.1158/1055-9965.EPI-09-1151. 
  • Ennis S, Jomary C, Mullins R, et al. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study.. Lancet. 2008, 372 (9652): 1828–34. PMID 18842294. doi:10.1016/S0140-6736(08)61348-3. 
  • Soejima M, Tachida H, Tsuneoka M, et al. Nucleotide sequence analyses of human complement 6 (C6) gene suggest balancing selection.. Ann. Hum. Genet. 2005, 69 (Pt 3): 239–52. PMID 15845028. doi:10.1046/j.1529-8817.2005.00165.x. 
  • Bulla R, Bossi F, Agostinis C, et al. Complement production by trophoblast cells at the feto-maternal interface.. J. Reprod. Immunol. 2009, 82 (2): 119–25. PMID 19665237. doi:10.1016/j.jri.2009.06.124. 
  • Gancz D, Donin N, Fishelson Z. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.. Mol. Immunol. 2009, 47 (2-3): 310–7. PMID 19864026. doi:10.1016/j.molimm.2009.09.016. 
  • Parham KL, Roberts A, Thomas A, et al. Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family.. Mol. Immunol. 2007, 44 (10): 2756–60. PMID 17257682. doi:10.1016/j.molimm.2006.11.022. 
  • Wu C, Ma MH, Brown KR, et al. Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.. Proteomics. 2007, 7 (11): 1775–85. PMID 17474147. doi:10.1002/pmic.200601006. 
  • Bailey SD, Xie C, Do R, et al. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.. Diabetes Care. 2010, 33 (10): 2250–3. PMC 2945168可免费查阅. PMID 20628086. doi:10.2337/dc10-0452. 

外部連結

激活途徑
  • 經典途徑(C
  • 凝集素途徑(L
  • 替代途徑(A
激活物/酶
前端反應
  • 經典途徑:C1英语Complement_component_1
    • C1q英语Complement_component_1q
    • C1r英语Complement_component_1r
    • C1s英语Complement_component_1s
  • C4英语Complement component 4
    • C4a英语C4a
    • C4b英语C4b
  • C2英语Complement component 2
  • 凝集素途徑:MASP-1/MASP-2
  • MBL
  • 替代途徑:B因子英语Complement factor B
  • D因子英语Complement factor D
  • 备解素英语Properdin(P因子)
中間反應
  • C3英语Complement component 3
    • C3a英语C3a
    • C3b英语C3b/iC3b英语iC3b
  • C5英语Complement component 5
    • C5a英语Complement component 5a
    • C5b英语Complement component 5b
  • C3轉化酶英语C3-convertase
  • C5轉化酶英语C5-convertase
末端通路
抑制物
  • CLA: C1抑制物英语C1-inhibitor
  • 衰變加速因子/CD59
  • I因子英语Complement factor I
  • CL: C4BP英语C4b-binding protein
  • A: H因子英语Factor H
補體受體英语Complement receptor
  • 補體受體1
功能
  • 膜攻擊複合物(MAC)
  • 調理作用英语Opsonization
  • 免疫黏附英语Immune adherence
  • 介導炎症
小作品圖示这是一篇與生物化學相關的小作品。您可以通过编辑或修订扩充其内容。